Results 211 to 220 of about 3,868,024 (353)

Orphan Drug Vistonuridine First Antidote to Severe Accidental 5FU Overexposure

, 2009
NULL AUTHOR_ID
openalex   +1 more source

Novel diagnostic approaches and cost–benefit balance of treatment of immune-mediated and rare disease in the era of biologic drugs: Lessons from the 15th Turin Congress on Immune Pathology and Orphan Disease [PDF]

, 2012
Dario Roccatello
openalex   +1 more source

Actigraphy against 32‐hour polysomnography in patients with suspected idiopathic hypersomnia

Journal of Sleep Research, EarlyView.
Summary Actigraphy, a tool known for investigating sleep–wake patterns at home, lacks scientific validation in hypersomnolent subjects. We aim to validate an actigraphy‐based sleep–wake prediction algorithm against 32‐h continuous polysomnography in patients with suspected idiopathic hypersomnia, and to compare its performance to predict sleep–wake ...
Tugdual Adam, Jérôme Tanty, Lucie Barateau, Yves Dauvilliers   +3 more
wiley   +1 more source

Correction to: Analysis of the first ten years of FDA’s rare pediatric disease priority review voucher program: designations, diseases, and drug development

Orphanet Journal of Rare Diseases
Catherine Mease, Kathleen L. Miller, Lewis J. Fermaglich, Jeanine Best, Gumei Liu, Erika Torjusen   +5 more
doaj   +1 more source

Debates over orphan drug pricing: a meta-narrative literature review. [PDF]

Orphanet J Rare Dis
Hanchard MS.
europepmc   +1 more source

Prevalence Rates of Frequent Dream Recall and Nightmares by Age, Gender and Sleep Duration in 16 Countries

Journal of Sleep Research, EarlyView.
ABSTRACT The present study aimed to describe the prevalence rates of frequent (i.e., at least weekly) dream recall and nightmares with consideration for differences in age, gender and sleep duration in 16 countries using equivalent assessment methods.
Courtney J. Bolstad, Bjørn Bjorvatn, Ngan Yin Chan, Frances Chung, Yves Dauvilliers, Luigi De Gennaro, Colin A. Espie, Brigitte Holzinger, Yuichi Inoue, Maria Korman, Adrijana Koscec Bjelajac, Anne‐Marie Landtblom, Tainá Macêdo, Kentaro Matsui, Ilona Merikanto, Charles M. Morin, Sérgio Mota‐Rolim, Thomas Penzel, Giuseppe Plazzi, Cátia Reis, Serena Scarpelli, Yun Kwok Wing, Michael R. Nadorff   +22 more
wiley   +1 more source

PHP6 QUANTITATIVE ANALYSIS OF THE INFLUENCE OF DISEASE AND PRODUCT CHARACTERISTICS ON ORPHAN DRUG PRICES IN EUROPE

, 2010
Samuel Aballéa, Mondher Toumi, AL Vataire, A. Millier, Michel Lamure   +4 more
openalex   +1 more source

The Future of Parasomnias

Journal of Sleep Research, EarlyView.
ABSTRACT Parasomnias are abnormal behaviours or mental experiences during sleep or the sleep–wake transition. As disorders of arousal (DOA) or REM sleep behaviour disorder (RBD) can be difficult to capture in the sleep laboratory and may need to be diagnosed in large communities, new home diagnostic devices are being developed, including actigraphy ...
Claudia Picard‐Deland, Matteo Cesari, Ambra Stefani, Jean‐Baptiste Maranci, Birgit Hogl, Isabelle Arnulf   +5 more
wiley   +1 more source

Present and Future of Central Disorders of Hypersomnolence

Journal of Sleep Research, EarlyView.
ABSTRACT Central disorders of hypersomnolence (CDH) are rare neurological conditions lumped by excessive daytime sleepiness (EDS) as primary complaint mostly arising at young age, including narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), idiopathic hypersomnia (IH), and Kleine‐Levin syndrome (KLS). Advances in clinical and translational research have
Francesco Biscarini, Lucie Barateau, Fabio Pizza, Giuseppe Plazzi, Yves Dauvilliers   +4 more
wiley   +1 more source

PHP102 From Value to Price: What Should Be the Path for Orphan Drugs? [PDF]

, 2012
Olivier Ethgen, Adam Hutchings, Pierrick Rollet, Baudouin Standaert   +3 more
openalex   +1 more source